---
title: Combined whole-body dynamic and static PET/CT with low-dose [<sup>18</sup>F]PSMA-1007
  in prostate cancer patients
date: '2024-01-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38286936/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240130170654&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In prostate cancer, low-dose (2 MBq/kg) [^(18)F]PSMA-1007
  LAFOV PET/CT can reduce static scan time by 50% without significantly compromising
  lesion detection rate and objective image quality. In addition, dynamic PET can
  elucidate molecular pathways related to the physiology of [^(18)F]PSMA-1007 in both
  tumor lesions and normal organs at the whole-body level. These findings unfold many
  of the potentials of the new LAFOV PET/CT technology in the field of PSMA-based
  diagnosis ...'
disable_comments: true
---
CONCLUSIONS: In prostate cancer, low-dose (2 MBq/kg) [^(18)F]PSMA-1007 LAFOV PET/CT can reduce static scan time by 50% without significantly compromising lesion detection rate and objective image quality. In addition, dynamic PET can elucidate molecular pathways related to the physiology of [^(18)F]PSMA-1007 in both tumor lesions and normal organs at the whole-body level. These findings unfold many of the potentials of the new LAFOV PET/CT technology in the field of PSMA-based diagnosis ...